Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.104 USD | +16.20% | +13.66% | -38.68% |
Mar. 27 | Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab | CI |
Feb. 15 | Kintara Therapeutics Continues to Evaluate Strategic Options | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 6.82M |
---|---|---|---|---|---|
Net income 2022 | -22M | Net income 2023 | -14M | EV / Sales 2022 | - |
Net cash position 2022 | 11.78M | Net cash position 2023 | 2.61M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.54
x | P/E ratio 2023 |
-0.43
x | Employees | 2 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.79% |
Latest transcript on Kintara Therapeutics, Inc.
1 day | +16.20% | ||
1 week | +13.66% | ||
Current month | -2.80% | ||
1 month | +2.67% | ||
3 months | -46.11% | ||
6 months | -97.39% | ||
Current year | -38.68% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 18-04-10 |
Greg Johnson
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 18-04-10 |
Tamara Favorito
BRD | Director/Board Member | 65 | 21-04-28 |
Laura Douglass
BRD | Director/Board Member | 59 | 20-06-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.104 | +16.20% | 32,247,395 |
24-03-27 | 0.0895 | -0.33% | 5,259,034 |
24-03-26 | 0.0898 | +0.79% | 2,532,528 |
24-03-25 | 0.0891 | -2.62% | 2,134,937 |
24-03-22 | 0.0915 | 0.00% | 3,003,083 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-38.68% | 4.06M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |